PCIB PCI Biotech Holding ASA

PCI Biotech Holding ASA - Annual Report 2023

PCI Biotech Holding ASA - Annual Report 2023

Oslo, Norway, April 26, 2024.

The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website

For further information, please contact:             

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                       

Ronny Skuggedal, CEO, , Mobile:  757



This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments



EN
26/04/2024

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech Holding ASA - Notice of Annual General Meeting 2024

PCI Biotech Holding ASA - Notice of Annual General Meeting 2024 Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements...

May 3, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech Holding ASA - Annual Report 2023

PCI Biotech Holding ASA - Annual Report 2023 Oslo, Norway, April 26, 2024.The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website For further information, please contact:              PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                        Ronny Skuggedal, CEO, , Mobile:  757This information is subject to the disclosure requirements pursuant to section 5...

April 26, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech second half 2023 interim results

PCI Biotech second half 2023 interim results Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was initiation of field testing in Q4 with an internat...

February 14, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Invitation to second half interim 2023 results presentati...

PCI Biotech: Invitation to second half interim 2023 results presentation Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made availab...

February 12, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech initiates field testing of its proprietary technology for ...

PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies. The partners have signed a collaborative research agreement with the purpose of testing PCI Biotech’s proprietary technology for gene therapy manufacturing in the partners’ pilot manufacturing process. PCI Biotech brings its novel and promising technology for viral vector manufacturing into the field testi...

October 13, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch